Literature DB >> 11336039

Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone.

G J Hengstman, H J Ter Laak, B G van Engelen, B G van Venrooij.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11336039      PMCID： PMC1737334          DOI： 10.1136/jnnp.70.5.706

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  3 in total

Review 1.  Idiopathic inflammatory myopathy: autoantibody update.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

Review 2.  Immune and myodegenerative pathomechanisms in inclusion body myositis.

Authors:  Christian W Keller; Jens Schmidt; Jan D Lünemann
Journal:  Ann Clin Transl Neurol       Date:  2017-05-16       Impact factor: 4.511

Review 3.  Emerging therapeutic options for sporadic inclusion body myositis.

Authors:  Lindsay N Alfano; Linda P Lowes
Journal:  Ther Clin Risk Manag       Date:  2015-09-25       Impact factor: 2.423
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.